Kerry Group plc, headquartered in Tralee, County Kerry, Ireland, and founded in 1972, develops, manufactures and supplies taste, nutrition and ingredient solutions to the global food, beverage, pharmaceutical, biotechnology and pet industries. The company operates principally through its Taste & Nutrition segment, which offers flavours, taste modulation systems such as Tastesense Advanced for sugar reduction; functional ingredients and actives including plant-based proteins, fibres, enzymes and probiotics; savoury and sweet solutions for bakery, snacks, beverages and dairy; beverage ingredients like coffee concentrates, creamers and syrups; foodservice solutions; and pharmaceutical excipients and cell nutrition products; alongside Kerry Dairy Ireland, which produces branded and private label chilled dairy products including cheese, butter and milk for Irish, UK and select international markets. Kerry conducts operations across more than 140 countries spanning Europe, the Americas, Asia-Pacific, the Middle East and Africa, serving food and beverage manufacturers, foodservice providers, pharmaceutical companies and retailers via approximately 25,000 employees worldwide. Recent developments include the divestment of Kerry Dairy Ireland to Kerry Co-Operative Creameries, with the co-op acquiring a 70% stake for €350 million in January 2025 and Kerry retaining 30% until a full handover by 2035 for €150 million; the initiation of a €300 million share buyback programme in June 2025; strategic investments in a new coffee manufacturing facility, enzyme capacity expansion in Ireland, cocoa capabilities in France and a Biotechnology Innovation Centre in Leipzig; and first-half 2025 results showing €3.5 billion revenue, 3% volume growth and EBITDA margin expansion to 16.1%.